Implementation preclinical evaluation methods for therapeutic radiopharmaceuticals with CXCR4 and SSTR2 as target

The chemokine receptor 4 (CXCR4) and somatostatin receptor 2 (SSTR2) are both clinically relevant cancer targets for imaging and therapeutic applications. The development of innovative diagnostic and therapeutic radiopharmaceuticals will allow precision personalized therapy of patients with otherwise limited or non-existing treatment alternatives. Preclinical in vitro evaluation methods for therapeutic radiopharmaceuticals will be implemented using CXCR4 or SSTR2 expressing cells. Next, relevant CXCR4+ and SSTR2+ tumor mouse models (local and systemic) will be developed to evaluate the pharmacokinetics and in vivo properties of the diagnostic and therapeutic radiotracers. Further, kidney and liver toxicity will be assessed by in vivo imaging using µSPECT and the therapeutic efficacy will be evaluated in a theranostic setting. Finally, GMP compliant production and quality control of the most promising radiopharmaceuticals will be implemented to allow future clinical translation.

Keywords:CXCR4, SSTR2, Targeted radionuclide therapy

Disciplines:Cancer diagnosis, Cancer therapy, Nuclear imaging